MX2016013245A - Regimen de dosificacion de liberacion inmediata de moduladores s1p. - Google Patents

Regimen de dosificacion de liberacion inmediata de moduladores s1p.

Info

Publication number
MX2016013245A
MX2016013245A MX2016013245A MX2016013245A MX2016013245A MX 2016013245 A MX2016013245 A MX 2016013245A MX 2016013245 A MX2016013245 A MX 2016013245A MX 2016013245 A MX2016013245 A MX 2016013245A MX 2016013245 A MX2016013245 A MX 2016013245A
Authority
MX
Mexico
Prior art keywords
immediate release
release dosage
modulator
dosage regimen
siponimod
Prior art date
Application number
MX2016013245A
Other languages
English (en)
Spanish (es)
Inventor
Wallstroem Erik
Legangneux Eric
Michel Rene Bouillot Philippe
Reynaud Emeric
Dehlke Frank
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52988364&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016013245(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016013245A publication Critical patent/MX2016013245A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2016013245A 2014-04-10 2015-04-08 Regimen de dosificacion de liberacion inmediata de moduladores s1p. MX2016013245A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461977816P 2014-04-10 2014-04-10
PCT/IB2015/052550 WO2015155709A1 (en) 2014-04-10 2015-04-08 S1p modulator immediate release dosage regimen

Publications (1)

Publication Number Publication Date
MX2016013245A true MX2016013245A (es) 2017-01-16

Family

ID=52988364

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013245A MX2016013245A (es) 2014-04-10 2015-04-08 Regimen de dosificacion de liberacion inmediata de moduladores s1p.

Country Status (16)

Country Link
US (4) US20170027907A1 (enExample)
EP (3) EP4074312A1 (enExample)
JP (1) JP6674903B2 (enExample)
KR (2) KR20220156981A (enExample)
CN (2) CN116650467A (enExample)
AU (2) AU2015246036A1 (enExample)
CA (1) CA2943598C (enExample)
CL (1) CL2016002562A1 (enExample)
IL (2) IL305337A (enExample)
MX (1) MX2016013245A (enExample)
PH (1) PH12016501965A1 (enExample)
RU (2) RU2020107732A (enExample)
SG (1) SG11201607894RA (enExample)
TW (1) TW201622721A (enExample)
WO (1) WO2015155709A1 (enExample)
ZA (1) ZA201606519B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (enExample) 2014-01-24 2018-02-24
MX2016013245A (es) * 2014-04-10 2017-01-16 Novartis Ag Regimen de dosificacion de liberacion inmediata de moduladores s1p.
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US20200316021A1 (en) * 2017-09-29 2020-10-08 Novartis Ag Dosing Regimen of Siponimod
CN111132677A (zh) * 2017-09-29 2020-05-08 诺华股份有限公司 西尼莫德的给药方案
HRP20250115T1 (hr) * 2018-03-01 2025-05-23 Astrazeneca Ab Farmaceutski pripravci koji sadrže (2s)-{(1s)-1-cijano-2-[4-(3-metil-2-okso-2,3-dihidro-1,3-benzoksazol-5-il)fenil]etil} -1,4-oksazepan-2-karboksamid
CA3106269A1 (en) 2018-07-17 2020-01-23 Insmed Incorporated Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
CN109908095A (zh) * 2019-04-08 2019-06-21 肇庆学院 一种西尼莫德片剂及制备方法
PH12022551043A1 (en) 2019-10-31 2023-05-03 Idorsia Pharmaceuticals Ltd Combination of a cxcr7 antagonist with an s1p1 receptor modulator
WO2021158838A1 (en) * 2020-02-07 2021-08-12 Argentum Pharmaceuticals Llc Dosage regimen of an s1p receptor modulator
AU2024206233A1 (en) 2023-01-06 2025-08-21 Insmed Incorporated Novel, reversible dpp1 inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171785A1 (en) * 2008-12-18 2011-07-28 Novartis Ag Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -a zetidine-3-carboxylic acid
MX367667B (es) 2008-12-22 2019-08-30 Novartis Ag Régimen de dosificación de un agonista de los receptores de s1p.
DK2379067T3 (en) * 2008-12-22 2015-12-07 Novartis Ag Dosing regimen to fingolimod FOR THE TREATMENT OF MULTIPLE SCLEROSIS
CA2773330C (en) * 2009-09-29 2021-11-02 Novartis Ag Dosage regimen of an s1p receptor modulator
BR112013017302B1 (pt) * 2011-01-07 2021-12-07 Novartis Ag Composição farmacêutica em fase sólida
WO2012095853A1 (en) 2011-01-10 2012-07-19 Novartis Pharma Ag Modified release formulations comprising sip receptor modulators
KR20140084041A (ko) * 2011-10-21 2014-07-04 노파르티스 아게 S1p 수용체 조절제 또는 효능제에 대한 투여 요법
MX2016013245A (es) * 2014-04-10 2017-01-16 Novartis Ag Regimen de dosificacion de liberacion inmediata de moduladores s1p.

Also Published As

Publication number Publication date
EP4074312A1 (en) 2022-10-19
CA2943598C (en) 2023-03-07
US20220016076A1 (en) 2022-01-20
SG11201607894RA (en) 2016-10-28
JP6674903B2 (ja) 2020-04-01
RU2016143979A (ru) 2018-05-14
US20190054065A1 (en) 2019-02-21
US20250041266A1 (en) 2025-02-06
ZA201606519B (en) 2017-11-29
JP2017510607A (ja) 2017-04-13
CL2016002562A1 (es) 2017-07-28
RU2715734C2 (ru) 2020-03-03
RU2016143979A3 (enExample) 2018-11-12
EP3831378A1 (en) 2021-06-09
AU2020203107B2 (en) 2021-10-21
IL247986A0 (en) 2016-11-30
CA2943598A1 (en) 2015-10-15
AU2015246036A1 (en) 2016-10-13
CN106456552A (zh) 2017-02-22
KR20160141841A (ko) 2016-12-09
CN116650467A (zh) 2023-08-29
PH12016501965A1 (en) 2017-01-09
EP3129020A1 (en) 2017-02-15
KR20220156981A (ko) 2022-11-28
US20170027907A1 (en) 2017-02-02
AU2020203107A1 (en) 2020-05-28
IL305337A (en) 2023-10-01
TW201622721A (zh) 2016-07-01
RU2020107732A (ru) 2020-03-30
WO2015155709A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
MX2016013245A (es) Regimen de dosificacion de liberacion inmediata de moduladores s1p.
DOP2016000291A (es) Composiciones y métodos para modular la expresión del factor b del complemento
MX2017005106A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
GT201500312A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
BR112016014410A2 (pt) terapia de combinação com vacina de neoantígeno
NI201500140A (es) Compuestos y composiciones terapéuticos
SV2017005489A (es) Terapias de combinación para el tratamiento de cánceres
MX2014015005A (es) Formas cristalinas de un modulador del receptor androgenico.
MX356052B (es) Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion.
CL2015001610A1 (es) Compuestos derivados de pirimido-[4,5-b]-quinolina-4,5(3h,10h)-dionas para utilizarse como un medicamento para el tratamiento de una enfermedad causada por una mutacion sin sentido; composicion y combinacion farmaceutica que los comprende.
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
MX2020004516A (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
BR112015025719A2 (pt) terapia contra o câncer
CL2020000812A1 (es) Semaglutida en la terapia médica.
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
AR099558A1 (es) Régimen de dosaje del compuesto fgf-18
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
BR112017009358A2 (pt) imunoterapia específica de peptídeo t terapêutico para uso no tratamento de metástase cerebral de um paciente com hla-2 positivo